» Articles » PMID: 16670331

Regulatory Roles for MD-2 and TLR4 in Ligand-induced Receptor Clustering

Overview
Journal J Immunol
Date 2006 May 4
PMID 16670331
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

LPS, a principal membrane component in Gram-negative bacteria, is recognized by a receptor complex consisting of TLR4 and MD-2. MD-2 is an extracellular molecule that is associated with the extracellular domain of TLR4 and has a critical role in LPS recognition. MD-2 directly interacts with LPS, and the region from Phe(119) to Lys(132) (Arg(132) in mice) has been shown to be important for interaction between LPS and TLR4/MD-2. With mouse MD-2 mutants, we show in this study that Gly(59) was found to be a novel critical amino acid for LPS binding outside the region 119-132. LPS signaling is thought to be triggered by ligand-induced TLR4 clustering, which is also regulated by MD-2. Little is known, however, about a region or an amino acid in the MD-2 molecule that regulates ligand-induced receptor clustering. MD-2 mutants substituting alanine for Phe(126) or Gly(129) impaired LPS-induced TLR4 clustering, but not LPS binding to TLR4/MD-2, demonstrating that ligand-induced receptor clustering is differentially regulated by MD-2 from ligand binding. We further show that dissociation of ligand-induced receptor clustering and of ligand-receptor interaction occurs in a manner dependent on TLR4 signaling and requires endosomal acidification. These results support a principal role for MD-2 in LPS recognition.

Citing Articles

Decoding nature: multi-target anti-inflammatory mechanisms of natural products in the TLR4/NF-κB pathway.

Zhao Y, Wu J, Liu X, Chen X, Wang J Front Pharmacol. 2025; 15:1467193.

PMID: 39877388 PMC: 11772364. DOI: 10.3389/fphar.2024.1467193.


Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target.

Zhang H, Thai P, Shivnaraine R, Ren L, Wu X, Siepe D Cell. 2024; 187(25):7143-7163.e22.

PMID: 39413786 PMC: 11645214. DOI: 10.1016/j.cell.2024.09.034.


Therapeutic Targeting of TLR4 for Inflammation, Infection, and Cancer: A Perspective for Disaccharide Lipid A Mimetics.

Heine H, Zamyatina A Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678520 PMC: 9864529. DOI: 10.3390/ph16010023.


Anti-Inflammatory Effects of Ginsenoside Rb3 in LPS-Induced Macrophages Through Direct Inhibition of TLR4 Signaling Pathway.

Xu H, Liu M, Chen G, Wu Y, Xie L, Han X Front Pharmacol. 2022; 13:714554.

PMID: 35401188 PMC: 8987581. DOI: 10.3389/fphar.2022.714554.


Lipopolysaccharide Recognition in the Crossroads of TLR4 and Caspase-4/11 Mediated Inflammatory Pathways.

Zamyatina A, Heine H Front Immunol. 2020; 11:585146.

PMID: 33329561 PMC: 7732686. DOI: 10.3389/fimmu.2020.585146.